Etoricoxib sales will expand through 2036, with powder at 74.6% within the form segment and ≥99.5% at 61.4% of the purity grade category in 2026. The market is estimated at USD 17.5 million in 2026 and is forecast to record a 1.4% CAGR between 2026 and 2036.